EMA And Commission Correct Altuvoct, Celldemic, Lytenava Active Substance Status Discrepancies

 
• By Ian Schofield

Lytenava, Outlook Therapeutics’ ophthalmic version of bevacizumab for wet AMD, has been given the INN bevacizumab gamma, but it is not a new active substance, the EU authorities have confirmed.

The question of what's new surrounded by wooden blocks
Determining what is a new active substance can be tricky. • Source: Shutterstock

More from Europe

More from Geography